drugset / Trial / NCT05338476
A Study of Effects of Selpercatinib (LY3527723) on Midazolam in Healthy Participants
Non-randomizedSequentialOpen-labelBasic science
Summary
The main purpose of this study is to assess the effect of selpercatinib on how fast midazolam gets into the blood stream and how long it takes the body to remove it when administered in healthy participants. Information about safety and tolerability will be collected. The study will last up to about 6 weeks, inclusive of screening period.
Timeline
- Start
- 2018-07-12
- Primary completion
- 2018-08-01
- Completion
- 2018-09-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Midazolam | Small molecule | 2 mg | Oral |
| Subject | Selpercatinib | Small molecule | 160 mg | Oral |
Indications
No indication recorded.